Successful monotherapy with autologous formalin-fixed tumor vaccine for a stage IV uterine cancer patient rejecting rational chemotherapy and immune-checkpoint-inhibitor treatment セルメディシン株式会社が紹介する自家がんワクチン療法に関する記事や、論文をご覧いただけます。

会社情報

紹介記事・論文

Successful monotherapy with autologous formalin-fixed tumor vaccine for a stage IV uterine cancer patient rejecting rational chemotherapy and immune-checkpoint-inhibitor treatment

Fukuda K, Ohno T. Successful monotherapy with autologous formalin-fixed tumor vaccine for a Stage IV uterine cancer patient who rejected rational chemotherapy and immune checkpoint inhibitor treatment. Clin Case Rep. 2023 Jun 8;11(6):e7513. doi: 10.1002/ccr3.7513.

Abstract

Key clinical message: To overcome patient-initiated treatment refusal because of fear of experiencing severe negative adverse events, mild immunotherapy using a cancer vaccine such as the autologous formalin-fixed tumor vaccine should be considered.

Abstract: A patient who refused chemotherapy and immune checkpoint inhibitor treatment for Stage IV uterine cancer after displaying circulating tumor cells and high microsatellite instability received monotherapy with autologous formalin-fixed tumor vaccine (AFTV). Following treatment, we observed regression of multiple lung metastases, suggesting that AFTV is an attractive treatment option.

Keywords: cancer vaccine; immunotherapy; monotherapy; uterine cancer.

注:弊社は病院やクリニックではなくバイオ企業であるため、症例報告や論文内容のWeb掲載は許容されています。

ご相談は無料です。
お気軽にお問い合わせください。